# A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Source: https://onco.cc/trials/nct06792695/  
OnCo record `nct06792695` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of FOLFIRI, Fluorouracil, FLOT in colorectal cancer, run by AstraZeneca, now recruiting.

## Summary

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer is a phase 2 interventional study registered as NCT06792695 by AstraZeneca, with 80 participants planned, started 2025-03-12 and due to reach its primary completion in 2027-06-30. Interventions recorded: Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06792695
- Phase: 2
- Setting: A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)
- Sponsor: AstraZeneca
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06792695: https://clinicaltrials.gov/study/NCT06792695

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06792695.json